Review Article
Published: 28 June, 2017 | Volume 1 - Issue 1 | Pages: 029-032
Mitomycin-C, first found its way into ophthalmic use in 1969, in Japan, where recurrent pterygia were successfully treated with the drug which is an antineoplastic / antibiotic agent isolated from the soil bacterium Streptomyces caespitosus [1]. It is an anti-metabolite with anti-proliferative effect on cells showing the highest rate of mitosis by inhibiting DNA synthesis and interferes with RNA transcription and protein synthesis [2].
CLINICAL USES
Read Full Article HTML DOI: 10.29328/journal.hceo.1001004 Cite this Article Read Full Article PDF
HSPI: We're glad you're here. Please click "create a new Query" if you are a new visitor to our website and need further information from us.
If you are already a member of our network and need to keep track of any developments regarding a question you have already submitted, click "take me to my Query."